TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01746303

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acid
Description: A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Blueberry powder
Description: Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo oil
Description: Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo powder
Description: Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
Study: NCT03090477

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmaceutical care and adherence aids
Description: Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
Study: NCT03762408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENKO 1
Description: 50 mg of HA/ 50 mg of CS in 5 ml

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Durolane
Description: 60 mg HA crosslinked in 3 ml
Study: NCT00528112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCS12
Description: Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCS16
Description: Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
Study: NCT04097431

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Response Blocking
Description: Physically preventing the response (i.e., precursor) from occurring.
Study: NCT04326920

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sargramostim
Description: Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sargramostim
Description: Inhalation via mesh nebulizer and/or IV administration upon Clinical deterioration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Standard of care
Study: NCT02313220

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral and Subcutaneous use.
Study: NCT03561675

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT00956163

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: magnetic resonance imaging
Description: Undergo whole-body MRI

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fluorine F 18 sodium fluoride
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo fluorine F 18 sodium fluoride PET/CT scan

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: technetium Tc 99m methylene diphosphonate
Description: Undergo technetium Tc 99m methylene diphosphonate bone scan
Study: NCT04326166

Intervention type: DRUG
Intervention: Metformin and Evogliptin
Description: Metformin and Evogliptin
Study: NCT01081054

Intervention type: OTHER
Group type: OTHER
Intervention: Ambulatory versus hospitalisation
Description: Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory versus hospitalisation
Description: Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
Study: NCT00956163

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04132531

Intervention type: PROCEDURE
Intervention: Bariatric (weight loss) surgery
Description: Surgical intervention for weight reduction, whereby the stomach is resected and the gastrointestinal tract is rerouted in the case of Roux-en-y gastric bypass, or the stomach is only resected in the case of sleeve gastrectomy.
Study: NCT01415362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit.
Study: NCT02134756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NutraStem Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NutraStem Placebo
Study: NCT00889590

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: 4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
Study: NCT02976298

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: comparison of different conditions of transcranial magnetic stimulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial magnetic stimulation
Description: comparison of different conditions of transcranial magnetic stimulation
Study: NCT02970799

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intranasal Neurostimulator
Description: The device delivers small electrical currents, activating nerves that stimulate the body's natural tear production system.
Study: NCT02900794

Intervention type: DEVICE
Group type: OTHER
Intervention: Gold Laser
Description: Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Microdebridement
Description: Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
Study: NCT02693808

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous fat injection
Description: Injection in one side with autologous fat and the other side with hyaluronic acid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous fat injection
Description: Injection in one side with autologous fat and the other side with hyaluronic acid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Injection in one side with autologous fat and the other side with hyaluronic acid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic acid injection
Description: Injection in one side with autologous fat and the other side with hyaluronic acid.
Study: NCT00461006

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: 45mg po daily
Study: NCT01415362

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Direct Current Stimulation
Description: For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm\^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.~The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit.
Study: NCT03206762

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Description: Jetstream Atherectomy with randomization to the Ranger or IN.PACT DCB Arm or the POBA+DCB (Ranger or IN.PACT) Arm
Study: NCT00461006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: 0.6mg po daily
Study: NCT03009786

Intervention type: OTHER
Intervention: Measurement of salivary flow
Description: A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
Study: NCT03759834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cochlear promontory stimulation
Description: Promontory stimulation is an established otologic procedure that was initially developed as a diagnostic tool to assess patient candidacy for cochlear implantation. Promontory stimulation is most commonly performed in the outpatient setting on an awake patient by placing a single insulated probe through a topically anesthetized tympanic membrane and applying monopolar current for several seconds to minutes. The initial session of promontory stimulation will define optimal stimulation parameters (i.e., location, current level, pulse-width, phase polarity), where maximal tinnitus suppression occurs with minimal or no auditory percept. Additional stimulation testing visits will confirm these findings.
Study: NCT03249636

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
Study: NCT04068402

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vivio System
Description: The Vivio System is an electronic auscultatory device and optical sensor, plus software application intended to provide support to the physician in the evaluation of heart sounds in patients. The product will analyze the acoustic signals of the heart and signals from a captured arterial (carotid) waveform. The analysis procedure will identify and analyze specific heart sounds and arterial waveform features captured by the Vivio device, to devise a scoring system for severe aortic stenosis.
Study: NCT03290846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secretin Human
Description: Randomized, single-blinded secretin hydrochloride infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Randomized, single-blinded saline infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: All subjects will undergo a cold exposure PET scan.
Study: NCT01944137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Intervention
Description: Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
Study: NCT00786669

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients \<0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefixime
Description: 8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
Study: NCT04540263

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow Cytometric analysis
Description: Measuring the level of IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokines in the serum
Study: NCT02764463

Intervention type: DEVICE
Group type: OTHER
Intervention: Fiber Reinforced Composite Fixed Partial Dentures
Description: All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
Study: NCT03179566

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Sheet
Description: Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information Sheet
Description: Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Deterra Drug Deactivation System
Description: This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
Study: NCT02600481

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low-pressure pneumoperitoneum
Description: Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: standard-pressure pneumoperitoneum
Description: Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
Study: NCT03133611

Intervention type: OTHER
Group type: OTHER
Intervention: Speech assessment
Description: Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech assessment
Description: Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.

Intervention type: OTHER
Group type: OTHER
Intervention: Speech assessment
Description: Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine clinical assessment
Description: Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine clinical assessment
Description: Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.

Intervention type: OTHER
Group type: OTHER
Intervention: Routine clinical assessment
Description: Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
Study: NCT03383861

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-ray Absorptiometry (DXA)
Description: BMD t-score derived from DXA scan

Intervention type: DIAGNOSTIC_TEST
Intervention: Dual-Energy X-ray Absorptiometry (DXA)
Description: BMD t-score derived from DXA scan
Study: NCT03289208

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: 30 mg of edaravone will be administered intravenously over 60 minutes.
Study: NCT01622959

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: -Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS\>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: -Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.~The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.~-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes \<30%. Treatment failure is defined as VAPS\>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion.
Study: NCT05627973

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Surgical replacement of aortic valves

Intervention type: DEVICE
Intervention: Aortic Valve Replacement
Description: Surgical replacement of aortic valves
Study: NCT02195908

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Neiguan(PC6) plus antiemetic drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single point Zhongwan(CV12) plus antiemetic drug

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: only antiemetic drug
Study: NCT04264858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immunoglobulin of cured patients
Description: 0.2g/kg, ivdrip, once a day, for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: γ-Globulin
Description: 0.2g/kg, ivdrip, once a day, for 3 days
Study: NCT00434408

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: chx once
Description: 4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CHX x 7 days
Description: 4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: dry cord care
Description: Household members are instructed to apply nothing to the newborn's umbilical cord stump.
Study: NCT02976298

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: transcranial magnetic stimulation
Description: comparison of different conditions of transcranial magnetic stimulation